MiR-202 Inhibits Cell Proliferation, Migration, and Invasion by Targeting Epidermal Growth Factor Receptor in Human Bladder Cancer

Overview

Journal Oncol Res

Specialty Oncology

Date 2018 Jan 5

PMID 29298735

Citations 21

Authors

Liqing Zhang

Jianjiang Xu

Gaodi Yang

Heng Li

Xiuxia Guo

Affiliations

Soon will be listed here.

Abstract

Recent studies have demonstrated that miR-202 is associated with several types of cancer; however, the expression and function of miR-202 have not been investigated in bladder cancer. We analyzed the expression of miR-202 in bladder cancer tissues and adjacent noncancerous tissues. The effect of miR-202 on the proliferation, migration, and invasion was evaluated by in vitro assays. The target gene of miR-202 was assessed by luciferase reporter assay. In this study, miR-202 was found to be significantly downregulated in bladder cancer cell lines and tissues and was highly correlated with the T classification, N classification, grade, and recurrence. Ectopic expression of miR-202 suppressed cell viability, colony formation, cell migration, and invasion in vitro and inhibited xenograft tumor growth in vivo. Inversely, downregulation of miR-202 had contradictory effects. The 3'-untranslated region (3'-UTR) of epidermal growth factor receptor (EGFR) was identified as a direct target of miR-202 using luciferase reporter assays, and knockdown of EGFR enhanced miR-202-inhibited cell proliferation, migration, and invasion. In conclusion, miR-202 suppresses bladder cancer carcinogenesis and progression by targeting EGFR, thereby representing a potential target for miRNA-based therapy for bladder cancer in the future.

Citing Articles

KAT5 Inhibitor NU9056 Suppresses Anaplastic Thyroid Carcinoma Progression through c-Myc/miR-202 Pathway.

Xu W, Xie L, Yang Y, Xu J, Cai S, Tian Y Int J Endocrinol. 2023; 2022:2014568.

PMID: 37342240 PMC: 10279498. DOI: 10.1155/2022/2014568.

Heat Shock Transcription Factor 2 Is Significantly Involved in Neurodegenerative Diseases, Inflammatory Bowel Disease, Cancer, Male Infertility, and Fetal Alcohol Spectrum Disorder: The Novel Mechanisms of Several Severe Diseases.

Tokunaga Y, Otsuyama K, Kakuta S, Hayashida N Int J Mol Sci. 2022; 23(22).

PMID: 36430241 PMC: 9691173. DOI: 10.3390/ijms232213763.

The microRNA-202 as a Diagnostic Biomarker and a Potential Tumor Suppressor.

Ahmed E, Rajendran P, Scherthan H Int J Mol Sci. 2022; 23(11).

PMID: 35682549 PMC: 9180238. DOI: 10.3390/ijms23115870.

Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Diagn Progn. 2022; 1(4):245-263.

PMID: 35403137 PMC: 8988954. DOI: 10.21873/cdp.10033.

Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.

Zheng Y, Xie L, Xu S, Yan W, Zhang H, Meng Y Mol Cell Biochem. 2021; 476(11):4031-4044.

PMID: 34244973 DOI: 10.1007/s11010-021-04211-4.

References

Kim K, Chadalapaka G, Pathi S, Jin U, Lee J, Park Y . Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol Cancer Ther. 2012; 11(9):1852-62. PMC: 3632183. DOI: 10.1158/1535-7163.MCT-12-0181. View

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

Manikandan R, Rodriguez O, Parada R, Palou Redorta J . Nonmuscle-invasive bladder cancer: what's changing and what has changed. Urologia. 2017; 84(1):1-8. DOI: 10.5301/uro.5000213. View

Zhao Z, Lv B, Zhang L, Zhao N, Lv Y . miR-202 functions as a tumor suppressor in non-small cell lung cancer by targeting STAT3. Mol Med Rep. 2017; 16(2):2281-2289. DOI: 10.3892/mmr.2017.6841. View

Liu J, Zheng M, Tang Y, Liang X, Yang Q . MicroRNAs, an active and versatile group in cancers. Int J Oral Sci. 2011; 3(4):165-75. PMC: 3469973. DOI: 10.4248/IJOS11063. View

Arfaoui A, Mejri S, Belhaj R, Karkni W, Chebil M, Rammeh S . Prognostic value of immunohistochemical expression profile of epidermal growth factor receptor in urothelial bladder cancer. J Immunoassay Immunochem. 2016; 37(4):359-67. DOI: 10.1080/15321819.2016.1146757. View

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

Jiang J, Huang J, Wang X, Quan Y . MicroRNA-202 induces cell cycle arrest and apoptosis in lung cancer cells through targeting cyclin D1. Eur Rev Med Pharmacol Sci. 2016; 20(11):2278-84. View

Kang M, Lee K, Lee H, Jeong C, Kwak C, Kim H . Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells. Int J Mol Sci. 2017; 18(2). PMC: 5343857. DOI: 10.3390/ijms18020321. View

10.

Liu S, Howell P, Riker A . Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells. Ann Surg Oncol. 2012; 20(5):1745-52. DOI: 10.1245/s10434-012-2467-3. View

11.

Sempere L . Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn. 2011; 11(8):813-27. PMC: 3220160. DOI: 10.1586/erm.11.69. View

12.

Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y . MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol. 2012; 41(3):869-75. PMC: 3582905. DOI: 10.3892/ijo.2012.1535. View

13.

Xiong Y, Wang R, Peng L, You W, Wei J, Zhang S . An integrated lncRNA, microRNA and mRNA signature to improve prognosis prediction of colorectal cancer. Oncotarget. 2017; 8(49):85463-85478. PMC: 5689623. DOI: 10.18632/oncotarget.20013. View

14.

Lopez-Aguilar J, Velazquez-Flores M, Simon-Martinez L, Avila-Miranda R, Rodriguez-Florido M, Ruiz-Esparza Garrido R . Circulating microRNAs as Biomarkers for Pediatric Astrocytomas. Arch Med Res. 2017; 48(4):323-332. DOI: 10.1016/j.arcmed.2017.07.002. View

15.

He B, Yin B, Wang B, Xia Z, Chen C, Tang J . MicroRNAs in esophageal cancer (review). Mol Med Rep. 2012; 6(3):459-65. DOI: 10.3892/mmr.2012.975. View

16.

Citri A, Yarden Y . EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7(7):505-16. DOI: 10.1038/nrm1962. View

17.

Feifei N, Mingzhi Z, Yanyun Z, Huanle Z, Fang R, Mingzhu H . MicroRNA expression analysis of mammospheres cultured from human breast cancers. J Cancer Res Clin Oncol. 2012; 138(11):1937-44. DOI: 10.1007/s00432-012-1272-5. View

18.

Olkhov-Mitsel E, Savio A, Kron K, Pethe V, Hermanns T, Fleshner N . Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. Transl Oncol. 2017; 10(2):168-177. PMC: 5293735. DOI: 10.1016/j.tranon.2017.01.001. View

19.

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

20.

Ling H, Zhang W, Calin G . Principles of microRNA involvement in human cancers. Chin J Cancer. 2011; 30(11):739-48. PMC: 4013296. DOI: 10.5732/cjc.011.10243. View